Aethlon Medical, Inc. (AEMD)

Market Cap	10.00M
Revenue (ttm)	30,233
Net Income (ttm)	-13.02M
Shares Out	20.74M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	0.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,617
Open	0.44
Previous Close	0.436
Day's Range	0.424 - 0.443
52-Week Range	0.39 - 2.73
Beta	0.90
Analysts	Buy
Price Target	7.14 (+1,564.7%)
Earnings Date	Nov 14, 2022

About AEMD

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for stud...

• Industry: Health Care Equipment & Supplies
• CEO: Timothy Rodell
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: AEMD

Full Company Profile

Financial Performance

In 2021, AEMD's revenue was $294,165, a decrease of -55.37% compared to the previous year's $659,104. Losses were -$10.42 million, 32.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AEMD stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 1,564.72% from the latest price.

Price Target

$7.14

(1,564.72% upside)

Analyst Consensus: Buy

Stock Forecasts